CARDIOVASCULAR
hamburger

Managing Heart Failure

Pulmonary Artery (PA) Pressure monitoring to improve your quality of life

If you have heart failure, changes in the pressure of blood flowing from your heart to your lungs through your pulmonary artery can signal worsening heart failure — even before you notice symptoms such as shortness of breath or weight gain.

One way your doctor can monitor your heart failure progression and help you manage it is through remote PA pressure monitoring from the comfort of your home with the CardioMEMS™ HF System. Based on the data your care team gets from the system, they can make adjustments to your medications or recommend lifestyle changes without you needing to go to the hospital or clinic.

The CardioMEMS HF System

The CardioMEMS HF System from Abbott is the first and only clinically proven PA pressure monitor that significantly reduces heart failure hospital admissions and improves quality of life.1 It has been clinically proven to reduce hospital readmissions by 57% over an average of 12 months.2

That’s important because:

  • Each time you’re hospitalized for heart failure, your heart sustains further damage. That damage may contribute to your heart failure getting worse.3
  • Repeat hospitalizations for heart failure remain a strong predictor of illness and death for heart failure patients.4
Early treatment for heart failure is essential. This chart shows the progression of heart failure and where pa pressure changes can be observed.

How the CardioMEMS HF System works

  1. Using a common surgical procedure, a tiny pressure-sensing device gets inserted into your pulmonary artery.
  2. A home electronic unit about the size of a queen-sized pillow lets you take daily PA pressure readings from the comfort of your home.
  3. The system sends these readings to your heart failure medical team through a secure website.
  4. Your care team reviews the readings and contacts you if a particular action or adjustment is necessary.

Regular monitoring helps you and your heart failure medical team get ahead of heart failure to slow the progression.

Watch a video about how the CardioMEMS HF System works

Talk to your doctor about your heart failure treatment options.

Talking to your doctor about heart failure can feel overwhelming, but it’s extremely important. Your doctor may discuss a variety of treatment options with you based on your symptoms, severity, and overall health.

Make the most of your time with your doctor by preparing before your appointment.

References

  1. Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M. F., Costanzo, M. R., Stevenson, L. W., … Yaday, J. S. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. The Lancet, 377(9766), 658-666. n=550. http://dx.doi.org/10.1016/S0140-6736(11)60101-3
  2. Shavelle DM, Desai AS, Abraham WT, et al. Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure Patients in Clinical Practice: 1-Year Outcomes from the CardioMEMS Post Approval Study. Presented at: ACC; March 17, 2019. SJM-MEM-0419-0510
  3. Gheorghiade, et al. Pathophysiologic Targets in Early AHFS. The American Journal of Cardiology. September 19, 2005;96(6A).
  4. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154:260-266.

MAT-2100733 v2.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.